RVMDGlobeNewsWire·May 31, 2026 at 08:06 AM

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine

Source: GlobeNewsWire

RVMDRevolution Medicines, Inc.

More RVMD News

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

GlobeNewsWire·2026-04-21